VerbatimParliament, as it happens

Givinostat

Asked by Martin WrigleyLiberal DemocratDepartment of Health and Social CareTabled Answered 20 January 2025UIN 23967

The question

To ask the Secretary of State for Health and Social Care, if he will have discussions with NICE on the potential merits of offering Givinostat for Duchenne muscular dystrophy.

Answered by Karin Smyth

There are no plans to have discussions with the National Institute for Health and Care Excellence (NICE) on offering givinostat for Duchenne muscular dystrophy. The NICE makes recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS independently, based on an assessment of their costs and benefits. The NHS in England is legally required to fund medicines recommended by the NICE, normally within three months of the publication of final guidance. The NICE is currently evaluating givinostat, and its Appraisal Committee will meet to consider its recommendations in May 2025.

Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →

Open this question in Verbatim →

Every written question, searchable

155,000 questions tabled since the election, with the answer each department gave — and the ones still unanswered, with the clock running. Free to search.

Search written questions →Read on Verbatim